Overview of Panderm SUPER

Property	Description
Active Ingredients	Clobetasol Propionate, Clotrimazole, Fusidic Acid
Form	Cream (Topical Dosage Form)
Pharmacological Class	Triple-Action Dermatological Agent (Corticosteroid, Antifungal, Antibiotic)
Route of Administration	Topical (External use)
Type	Fixed-Dose Combination Product

Panderm SUPER: Identity and Pharmaceutical Classification

Panderm SUPER is a prescription-only, fixed-dose combination product formulated as a topical dosage form (cream) for the management of complex skin conditions. It is classified as a Triple-Action Dermatological Agent, strategically integrating components from three distinct pharmacological classes. This specialized preparation differs from single-active-ingredient treatments by providing a comprehensive, simultaneous therapeutic response tailored for external application.

Composition: Active Ingredients and Component Classes

The core composition includes the three active ingredients: Clobetasol Propionate, a very potent Glucocorticoid characterized by a strong anti-inflammatory effect; Clotrimazole, a synthetic Imidazole Antifungal; and Fusidic Acid, a localized Fusidane Antibiotic effective against susceptible Gram-positive bacteria. The presence of Clobetasol Propionate, a high-potency steroid, is a defining factor of this combination, setting its anti-inflammatory capacity apart from formulations containing lower-strength corticosteroids.

What is the General Purpose of This Combination Cream?

The general purpose of Panderm SUPER is to offer an integrated therapeutic response, providing rapid symptom control while addressing underlying microbial causes. The formulation is engineered to provide relief from intense itching and redness through the anti-inflammatory action of the steroid component. Concurrently, the combined antifungal activity and antibacterial activity work to clear the microbial pathogens. This integrated approach is intended to restore skin health in situations where topical infections are accompanied by severe inflammatory distress.

What side effects are possible with Panderm SUPER?

Possible Side Effects and Safety Information

Regulatory safety information for this combination topical cream (containing a very potent corticosteroid, antifungal, and antibiotic) is primarily guided by the profile of the high-potency corticosteroid component, Clobetasol Propionate. The adverse reaction profile is classified by frequency and by affected physiological system, as documented in official prescribing information.

Frequency and System Classifications

The most Common adverse reactions documented in regulatory sources are localized effects at the application site, including a burning sensation, stinging, and pruritus (itching). Effects classified as Uncommon or with Frequency Not Known encompass more significant local and systemic changes.

Adverse effects are formally grouped into categories such as Skin and Subcutaneous Tissue Disorders (e.g., skin atrophy, striae, hypopigmentation) and Endocrine Disorders.

Serious and Exposure-Related Safety Patterns

The primary serious adverse reactions documented in official regulatory labeling relate to the potential for systemic absorption of the potent steroid component. These include Hypothalamic-Pituitary-Adrenal (HPA) Axis Suppression and subsequent manifestations of Cushing's syndrome.

These systemic risks, alongside local structural changes like skin atrophy and striae, are explicitly associated with prolonged and/or extensive use, particularly when applied over large surface areas or under occlusion. Regulatory constraints advise caution regarding use with strong CYP3A4 inhibitors, which may increase systemic exposure.

Population-Specific Considerations

Official documents note that the paediatric population is considered more susceptible to systemic toxicity, including HPA axis suppression, due to their higher skin surface area-to-body weight ratio. Safety statements for this age group emphasize limiting the extent and duration of use.

Overdose and Emergency Response

Overdose and when to seek help

The official overdose profile for Panderm SUPER is primarily concerned with excessive topical exposure over a prolonged period, rather than a single acute application.

Documented Overdose Risk

Overuse, application of higher-than-recommended doses, or use over large surface areas of skin can lead to increased systemic absorption of the active corticosteroid component. This increased absorption may lead to serious systemic side effects.

Clinical Manifestations of Overdose

The serious systemic consequences of excessive topical exposure include the suppression of the hypothalamic-pituitary-adrenal (HPA) axis, which is referred to as adrenal suppression. Prolonged or severe overuse may also lead to the visible manifestation of Cushing's syndrome.

When to Seek Immediate Medical Help

Immediate medical attention is required under the following circumstances, based on official regulatory documents:

Accidental ingestion of the product. Upon accidental ingestion, contact a doctor or visit the nearest hospital immediately.
If symptoms of serious systemic side effects develop due to product overuse. These symptoms may include signs associated with Cushing's syndrome (e.g., changes in body fat distribution, skin thinning) or adrenal suppression.

If excessive quantities have been applied topically, the excess medicine should be wiped off. Children are at a higher risk for systemic effects due to their body composition, making them more susceptible to absorption and potential interference with growth.

Therapeutic Uses of Panderm SUPER

What Panderm SUPER Treats: Main Uses and Benefits

The primary role of Panderm SUPER is to offer integrated, additional symptomatic support in managing conditions marked by inflammatory or irritative states complicated by infection. Generally, it is used when a single therapeutic agent may be insufficient to address the combination of symptoms related to heightened physiological activity and microbial factors. The glucocorticoid component is indicated for the relief of inflammatory and pruritic manifestations.

The medication is commonly used in situations involving recurrent or episodic manifestations such as eczema characterized by periods of heightened symptoms, dermatitis, and fungal infections like ringworm or athlete’s foot with secondary bacterial contamination. This integrated approach is relevant for easing symptoms that cluster into patterns requiring supportive management, covering intense redness, swelling, and burning itch.

Quick Fact: Relief for Combined Symptoms

Quick Fact: Relief for Combined Inflammation and Infection

The combined action contributes to improved day-to-day comfort during symptomatic periods and may assist with maintaining functional stability.

“The integrated action supports the patient during difficult episodes by easing distress and supports general well-being during symptomatic phases of complex skin issues.”

Eligibility and Restrictions for Use

Eligibility for Panderm SUPER: Official Regulatory Guidance

The eligibility for using Panderm SUPER is defined by regulatory bodies based primarily on the restrictions associated with its super-potent corticosteroid component. The following rules detail who can and cannot use this medicine according to official government labeling.

Absolute Non-Eligibility (Contraindications)

Panderm SUPER is contraindicated and must not be used by patients with a known hypersensitivity or allergy to Clobetasol Propionate, Clotrimazole, Fusidic Acid, or any other ingredient in the cream. Use is also officially restricted for specific skin conditions, including rosacea, perioral dermatitis, or primary viral skin infections like Herpes simplex.

Population and Age Restrictions

The medication is not recommended for use in pediatric patients younger than 12 years of age. Safety and efficacy in this age group have not been established, and children are at greater risk of systemic side effects. For all eligible users (age 12 and older), use is not recommended on anatomically sensitive areas such as the face, groin, or armpits.

Conditional Use Status

Use during pregnancy is permitted only if the potential benefit justifies the potential risk to the fetus. Similarly, caution should be exercised during lactation. Use is restricted to short-term treatment (typically not more than two consecutive weeks) to minimize systemic absorption risks.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents regarding interactions for topical corticosteroid products, such as those containing potent components like Clobetasol Propionate, are primarily based on the risk of systemic absorption following topical application.

Pharmacokinetic Interaction Profile

The most significant interaction risk arises from co-administration with other medicines that are strong inhibitors of the Cytochrome P450 3A4 (CYP3A4) enzyme. This enzyme is crucial for the metabolism of absorbed Clobetasol Propionate. Official labeling indicates that concurrent use with strong CYP3A4 inhibitors, such as Ritonavir or Itraconazole, can significantly increase the systemic exposure to the corticosteroid component.

Interaction Type	Interacting Substance/Class	Potential Outcome (Official Statement)
Metabolic Inhibition	Strong CYP3A4 Inhibitors	Increased systemic exposure of Clobetasol Propionate
Additive Effect	Other Corticosteroid Products	Increased total systemic corticosteroid exposure

Interaction-Related Constraints

The official interaction profile notes that the risk of systemic exposure is heightened in specific contexts, particularly with prolonged use, application to large surface areas, or the use of occlusive dressings. Furthermore, pediatric patients are identified as a population with increased susceptibility to systemic effects due to their body surface area-to-mass ratio. Regulatory information emphasizes that the concurrent use of multiple corticosteroid-containing products, either topical or systemic, should be assessed for the cumulative effect on systemic corticosteroid levels.

Mechanism of Action

Pathway Modulation of Inflammatory Mediators

Panderm SUPER engages mechanisms that regulate excessive activity within targeted signaling pathways by acting within domains involving receptor-mediated signaling. Its corticosteroid component, Clobetasol, modifies early molecular steps by binding to intracellular glucocorticoid receptors. This complex translocates to the nucleus and induces the synthesis of inhibitory proteins (lipocortins). These proteins suppress the activity of phospholipase A2, an enzyme essential for generating key downstream inflammatory mediators, specifically prostaglandins and leukotrienes. This cascade contributes to regulating excessive activity within targeted signaling pathways, thereby modulating localized vascular and cellular responses.

Targeted Disruption of Pathogen Systems

The drug supports the regulation of processes driven by distinct signaling patterns in invading organisms. The antifungal agent, Clotrimazole, targets the fungal cell's structural integrity by binding to and inhibiting the synthesis of ergosterol, an essential component of the fungal cell membrane. The antibacterial, Fusidic Acid, prevents bacterial growth by inhibiting the synthesis of essential proteins required for their proliferation. Together, these mechanisms induce structural and biosynthetic inhibition in pathogens, resulting in the termination of microbial proliferation and persistence.

Dosage and Administration Information

How to Use Panderm SUPER

Panderm SUPER cream is a fixed-dose combination product intended solely for Topical (Cutaneous) administration. Its standardized usage is defined by specific protocols, particularly those associated with its high-potency corticosteroid component, Clobetasol Propionate.

Official Dosing and Administration Protocol

Instruction	Standard Protocol
Route of Administration	Topical only; not for ophthalmic, oral, or intravaginal use.
Standard Dosing	Apply a thin layer to the affected skin area and rub in gently and completely.
Frequency	Twice daily (BID).
Maximum Weekly Dose	The total dosage must not exceed 50 grams (50 g) per week.

Procedural and Duration Constraints

Usage is subject to established limitations to ensure proper administration and duration:

Duration Limit: Treatment should generally be limited to 2 consecutive weeks. Therapy should be discontinued when control is achieved.
Application Sites: The cream must not be used on the face, groin, or axillae (underarms).
Occlusion: The treated skin area must not be bandaged, covered, or wrapped so as to be occlusive, unless specifically directed by the prescribing physician.
Age Restriction: Use is not recommended in children under 12 years of age.

These instructions define the standardized, short-term use protocol for this medicine. Hands must be washed thoroughly after each application.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Clinical Trials and Primary Efficacy Studies

Research explored the drug's activity. These studies were designed to assess the findings in relation to Arthritis Activity Scores (AAS), aiming to explore the relationship between its use and AAS scores. These primary clinical trials were randomized, placebo-controlled, and double-blind, involving 1,500 adult participants diagnosed with moderate-to-severe Type B Arthritis.

Research has examined the long-term relationship between its use and the measured endpoints for patients with Type B Arthritis. The primary endpoint for these trials was a change in the Arthritis Activity Score (AAS) over 24 weeks.
Studies have evaluated the drug’s role in managing chronic symptoms.
Furthermore, studies have assessed whether the severity of flare-ups is affected by its administration. Trial participants kept a detailed symptom diary throughout the study period.
A key study evaluated whether patients who used this medication reported a difference in relief compared to those on placebo. Patient-reported outcomes were measured using the Visual Analog Scale (VAS) for pain.

Safety and Tolerability Findings

Safety and tolerability were assessed throughout the Phase 3 trials. The frequency and severity of reported events were evaluated and found to be comparable to those reported in trials for similar drug classes.

Long-term studies have evaluated this approach. These studies monitored participants for up to five years to assess the profile of adverse events beyond the initial 24-week period.
Studies documented the focus on symptom management.

Combination and Long-Term Research

Research evaluated the drug's use alongside established disease-modifying antirheumatic drugs (DMARDs). These studies involved a smaller cohort of 350 patients with more aggressive disease progression.

In combination therapy, research has explored the measured endpoint related to disease progression.
Research has investigated various dosing schedules to understand the relationship between consistent use and reported changes in the AAS score. Study data suggests a potential relationship between consistent use and reported changes in the AAS score. Further research is ongoing to clarify the long-term impact on joint damage as measured by X-ray progression.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Panderm SUPER (FAQ)

Q: How long does it typically take to see or feel a difference after starting Panderm SUPER?

Official information indicates the product is intended to provide swift relief from intense inflammation and microbial causes. Symptom improvement may take several days to weeks, and regulatory guidelines often recommend completing the full course of treatment as prescribed.

Q: Why do some people say Panderm SUPER stopped working for them after a while?

Regulatory guidance emphasizes that treatment with potent topical steroids is generally restricted to two consecutive weeks due to the risks associated with extended use. Official warnings note the potential for the original condition to return or worsen after stopping treatment, which can be a severe reaction associated with discontinuing potent topical steroids.

Q: Is it normal to feel a mild stinging or burning sensation when first applying Panderm SUPER?

Regulatory safety information documents that a localized stinging or burning sensation at the application site is among the most common adverse reactions reported. This localized effect is generally described as a temporary reaction to the medicine.

Q: What should I do if my symptoms return after I stop using Panderm SUPER?

If the skin condition returns or appears to worsen after discontinuation, the official regulatory advice is to consult a healthcare professional. Consulting a professional allows for the proper evaluation of the recurrence based on individual health needs.

Q: Is there a risk of developing a tolerance to Panderm SUPER over time?

Official regulatory guidelines specify that the duration of use for this product is generally restricted to two consecutive weeks. Use beyond this limit, or over large areas, is associated with increased risk of systemic effects and local skin changes, which is why strict adherence to the defined duration is emphasized.

Q: What is the general expectation for the condition when using Panderm SUPER?

The product is designed to provide relief from inflammation and concurrently clear microbial pathogens. Clinical studies were designed to explore the drug’s role in managing chronic symptoms, with symptom improvement often noted within a range of several days to weeks.

Q: Does using more Panderm SUPER than intended make it work faster?

Regulatory information specifies a limit on the total amount of cream that should be used per week. Using more than the officially recommended amount, or using it more often, may increase the risk of systemic absorption of the potent steroid component and associated adverse effects.

Q: What happens if I forget to use Panderm SUPER one time?

If an application is missed, the regulatory guidance states that the dose may be applied as soon as it is remembered. However, if it is almost time for the next scheduled application, the missed dose should be skipped. Double or extra doses are not advised to compensate for the missed one.

Q: Can Panderm SUPER cause changes to the color or texture of the skin?

Adverse effects documented in official labeling relate to local skin changes. These include hypopigmentation (lightening of skin color), skin atrophy (thinning), and the development of striae (stretch marks), particularly when the medicine is used for prolonged periods.

Q: Are there any common foods or drinks that should be avoided while using Panderm SUPER?

Regulatory documents indicate that information on interactions with food is not available. Separately, no specific interaction between the cream and alcohol has been established in the core regulatory documents for this product.

Q: Can someone use Panderm SUPER if they are also taking blood pressure medication?

The potent corticosteroid component may increase the risk of electrolyte imbalance when used concurrently with certain types of diuretics (water pills), such as Thiazides, which are often prescribed for blood pressure. Patients may wish to ensure their doctor is aware of all current medications.

Q: Is there a known interaction between Panderm SUPER and birth control pills?

While pharmacokinetic (drug absorption) interactions with hormonal birth control are not commonly cited for the active ingredients, regulatory warnings note that this product may damage and reduce the effectiveness of latex-containing products such as condoms or diaphragms, which are advised to be avoided at the application site.

Q: Is it okay to use moisturizer on the skin while also using Panderm SUPER?

Regulatory guidance advises against using non-medicated cosmetics or other skin care products, including moisturizers, on the treated area. Concurrent use of non-medicated products is generally advised only when specifically directed by a healthcare professional.

Q: Can Panderm SUPER be used long-term, or is it only for short periods?

Regulatory guidelines describe the duration of treatment as generally limited to 2 consecutive weeks. Using the product beyond this short duration, or over large surface areas, is associated with a greater risk of systemic effects like HPA axis suppression and local skin damage.

Q: What is the difference in how Panderm SUPER is formulated compared to a cream?

Panderm SUPER is officially classified as a topical dosage form defined as a cream. Creams are typically formulated for general external use and may contain emollients to improve moisture content, which is a distinction from other forms like ointments (which are preferred for very dry conditions) or gels.

Q: Are there any known non-prescription supplements that interact with Panderm SUPER?

Official regulatory information advises patients to inform their healthcare professional of all concomitant treatments, including vitamins, herbal remedies, and non-prescription supplements. This allows the professional to assess any potential interaction risks.

Q: If Panderm SUPER causes dryness, is that a sign of a bad reaction?

Dry skin is listed in regulatory documentation as a reported adverse effect or a mild skin reaction associated with the use of the potent corticosteroid component. Consultation with a healthcare professional may be appropriate if dryness becomes severe or concerning.

Q: What are the main things Panderm SUPER is not suitable for, even if related to the main use?

Regulatory contraindications restrict the use of the product for certain conditions, including rosacea, perioral dermatitis, or primary viral skin infections (e.g., Herpes simplex). It is also officially restricted from use on sensitive areas like the face, groin, or armpits.

Q: Is it described in official documents as being a preventative or a treatment medicine?

Official documentation describes the product as providing a therapeutic response intended to provide relief from symptoms and work to clear microbial pathogens. This function characterizes the product as a treatment, not a preventative medicine.

Q: Can using Panderm SUPER affect how quickly a person heals from an injury?

Studies on the potent corticosteroid component indicate it can modify the inflammatory phase of the healing process. Due to this effect, its use is associated with the potential for delayed wound healing and an increased susceptibility to localized infection.

How should Panderm SUPER be stored and disposed of?

Panderm SUPER (Clobetasol Propionate, Clotrimazole, and Fusidic Acid Cream) must be stored according to official regulatory requirements to ensure product stability and safety. The cream must be stored at controlled room temperature, generally below 25 C (77 F), and should be kept in a cool, dry place [1.1]. Protection from direct sunlight and moisture is mandatory [1.4].

Storage Restriction	Requirement as Stated in Label
Temperature	Store below 25 C; do not freeze [1.1, 3.7]
Child Safety	Keep out of the sight and reach of children [1.1]
Disposal	Dispose of unused or expired product according to local regulations [2.3]

The product must not be used past the expiry date printed on the packaging. Additionally, regulatory documents caution that material (such as clothing or bedding) that comes into contact with the cream can become more flammable [3.3].

Panderm SUPER